BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10094893)

  • 1. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
    Amezcua CA; Zheng W; Muderspach LI; Felix JC
    Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
    Orejuela FJ; Ramondetta LM; Smith J; Brown J; Lemos LB; Li Y; Hollier LM
    Gynecol Oncol; 2005 May; 97(2):483-8. PubMed ID: 15863148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Wheeler DT; Bristow RE; Kurman RJ
    Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps.
    Taylor LJ; Jackson TL; Reid JG; Duffy SR
    BJOG; 2003 Sep; 110(9):794-8. PubMed ID: 14511960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
    Ørbo A; Kaino T; Arnes M; Larsen K; Pettersen I; Moe B
    Acta Obstet Gynecol Scand; 2009; 88(11):1234-42. PubMed ID: 19900140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
    Dai D; Kumar NS; Wolf DM; Leslie KK
    Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
    Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
    Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study.
    Akesson E; Gallos ID; Ganesan R; Varma R; Gupta JK
    Acta Obstet Gynecol Scand; 2010 Mar; 89(3):393-8. PubMed ID: 20199355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: An approach using multiparameter flow cytometry.
    Morsi HM; Leers MP; Radespiel-Tröger M; Björklund V; Kabarity HE; Nap M; Jäger W
    Gynecol Oncol; 2000 Apr; 77(1):11-7. PubMed ID: 10739685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia.
    Miranda MC; Mazur MT
    Arch Pathol Lab Med; 1995 May; 119(5):458-60. PubMed ID: 7748076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study.
    Rattanachaiyanont M; Angsuwathana S; Techatrisak K; Tanmahasamut P; Indhavivadhana S; Leerasiri P
    J Obstet Gynaecol Res; 2005 Apr; 31(2):98-106. PubMed ID: 15771634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.
    Penner KR; Dorigo O; Aoyama C; Ostrzega N; Balzer BL; Rao J; Walsh CS; Cass I; Holschneider CH
    Gynecol Oncol; 2012 Mar; 124(3):542-8. PubMed ID: 22079678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.